Difference between revisions of "Paclitaxel (Taxol)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http:// | + | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]</ref><ref>[[Media:Paclitaxel.pdf | Paclitaxel (Taxol) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | <br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | ||
| Line 27: | Line 27: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http:// | + | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref> |
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref> | ||
Revision as of 03:54, 20 July 2015
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Head and neck cancer
- Melanoma
- Non-small cell lung cancer
- Ovarian cancer
- Penile cancer
- Prostate cancer
- Sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Uterine cancer
Patient drug information
- Paclitaxel (Taxol) package insert[1]
- Paclitaxel (Taxol) patient drug information (Chemocare)[3]
- Paclitaxel (Taxol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/29/1992: Initial FDA approval (label is not available)
- 4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:
- First-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Taxol is indicated in combination with cisplatin.
- The treatment of breast cancer after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- The second-line treatment of AIDS-related Kaposi's sarcoma.
- 6/30/1998: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
- 10/25/1999: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Also known as
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abitaxel | Altaxel | Anzatax | Anzatec | APO-Paclitaxel | Asotax | Betaxel | Bristaxol |
| Britaxol | Clitaxel | Cytax | Daburex | Dalys | Drifen | Ebetaxel | Formoxol |
| Genaxol | Genetaxyl | Gros | Ifaxol | Intaxel | LEP-ETU | LI PU SU | Magytax |
| Medixel | Mitotax | Neotacs | Neotaxan | Neotaxl | Ofoxel | Oncotaxel | Onxol |
| Paclitax | Paclitaxel | Paclitaxel-GRY | Paclitaxel APS | Paclitaxel Comp | Paclitaxel Delta Farma | Paclitaxel Ebewe | Paclitaxel Hexal |
| Paclitaxel Lens | Paclitaxel Mayne | Paclitaxel Microsules | Paclitaxel Servycal | Paclitaxin | Pacliteva | Pacxel | Padexol |
| Paklitaxfil | Panataxel | Parexel | Paxene | Paxenor | Paxus | Petaxel | Phyxol |
| Poltaxel | Praxel | Ribotax | Sindaxel | Taclipaxol | Tarvexol | Taxocris | Taxodiol |
| Taxol | Taxol Semi-Synthetic | Taxomedac | Taycovit | TE SU | Teva-Paclitaxel | Unitaxel | Yewtaxan |
| ZI SU | |||||||
References
Categories:
- Drug index
- Chemotherapy
- Intracavitary chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Vesicant chemotherapy
- Taxanes
- Microtubule inhibitors
- Aggressive Non-Hodgkin lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Esophageal cancer medications
- Head and neck cancer medications
- Melanoma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Penile cancer medications
- Prostate cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Uterine cancer medications
- Drugs FDA approved in 1992